[The efficacy and safety of Erenumab in patients with high-frequency episodic migraine according to the first Russian real-life study of the Research Center of Neurology].
Larisa A DobryninaMariia V GubanovaAnastasia V BelopasovaE V BaydinaM A AfanasevPublished in: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2022)
Real-life study confirmed the efficacy and safety of Erenumab in the treatment of HFEM, a decrease in the severity of comorbid anxiety and depression, and social maladjustment.